Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q4 FY20 results · Jan–Mar 2020
Morepen Laboratories reported revenue from operations of ₹206.60 crore (down 5.5% from Q4 FY19) and net profit of ₹11.02 crore (up 5.0% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 206.60 | 218.72 | −5.5% | 230.06 | −10.2% |
| Other income | 1.78 | 1.03 | +73.7% | 4.60 | −61.2% |
| Total income | 208.39 | 219.74 | −5.2% | 234.66 | −11.2% |
| Profit before share of associates & JVs and tax | 11.36 | 10.70 | +6.2% | 10.83 | +5.0% |
| Share of profit/(loss) of associates & JVs | 0.00 | 0.00 | 0.00 | ||
| Net profit for the period | 11.02 | 10.49 | +5.0% | 10.82 | +1.9% |
| EPS, basic (₹) | 0.25 | 0.23 | +8.7% | 0.24 | +4.2% |
| Net margin (%) | 5.3 | 4.8 | 4.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 189.15 | 206.07 | −8.2% | 213.49 | −11.4% |
| Other income | 1.72 | 1.03 | +67.5% | 4.60 | −62.6% |
| Total income | 190.87 | 207.10 | −7.8% | 218.09 | −12.5% |
| Profit before tax | 9.48 | 9.22 | +2.8% | 9.91 | −4.3% |
| Net profit for the period | 9.48 | 9.22 | +2.8% | 9.91 | −4.3% |
| EPS, basic (₹) | 0.21 | 0.21 | +0.0% | 0.22 | −4.5% |
| Net margin (%) | 5.0 | 4.5 | 4.6 |
Consolidated
- Filed with BSE
- 22 Jun 2020, 19:08 IST
- Board meeting
- 22 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jun 2020, 19:08 IST
- Board meeting
- 22 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE